Procaps Group Intrinsic Value – PROCAPS GROUP Reports USD 84.2 Million Revenue in First Quarter of Fiscal Year 2023, Down 1.7% from Last Year
June 12, 2023
🌥️Earnings Overview
On June 6 2023, PROCAPS GROUP ($NASDAQ:PROC) reported total revenue of USD 84.2 million and net income of USD 6.6 million for the first quarter of the 2023 fiscal year, ending on March 31. This represented a 1.7% decrease in revenue and a 59.8% decrease in net income compared to the same period in the previous year.
Analysis – Procaps Group Intrinsic Value
GoodWhale has conducted an in-depth analysis of PROCAPS GROUP‘s finances and have come to the conclusion that the fair value of PROCAPS GROUP’s share is around $9.0. This figure was calculated by GoodWhale’s proprietary Valuation Line, which uses a unique algorithm to provide accurate and timely stock price estimations. At the moment, PROCAPS GROUP’s shares are being traded at a price of $4.3, which is undervalued by a staggering 52.3%. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Procaps Group. More…
| Total Revenues | Net Income | Net Margin |
| 408.45 | 32.72 | -0.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Procaps Group. More…
| Operations | Investing | Financing |
| 10.88 | -29.7 | -22.06 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Procaps Group. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 441.72 | 436.55 | 0.05 |
Key Ratios Snapshot
Some of the financial key ratios for Procaps Group are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.1% | 2.3% | 16.9% |
| FCF Margin | ROE | ROA |
| -5.3% | 1668.4% | 9.8% |
Peers
The company was founded in 1978 and is headquartered in Colombia. Procaps Group SA’s main competitors are Albert David Ltd, Denis Chem Lab Ltd, and Glenmark Life Sciences Ltd.
– Albert David Ltd ($BSE:524075)
David’s market cap is currently at 3.36B, with a ROE of 8.67%. The company is known for their wide array of products and services, including their flagship product, the David Sheild. The company has been in operation for over 60 years and is a trusted name in the industry.
– Denis Chem Lab Ltd ($BSE:537536)
Denis Chem Lab Ltd is a publicly traded company with a market capitalization of 1.3 billion as of 2022. The company has a return on equity of 9.33%. Denis Chem Lab Ltd is engaged in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products. The company was founded in 1981 and is headquartered in Mumbai, India.
– Glenmark Life Sciences Ltd ($BSE:543322)
Glenmark Life Sciences Ltd is a pharmaceutical company with a market cap of 51.27B as of 2022. The company has a return on equity of 16.91%. Glenmark manufactures and markets a wide range of pharmaceutical products in India and internationally. The company’s product portfolio includes drugs in the areas of anti-infectives, cardiovascular, dermatology, diabetes, and respiratory. Glenmark also has a strong presence in the generic drug market in the United States.
Summary
Investors should consider PROCAPS GROUP‘s first quarter of the fiscal year ending on March 31 2023, in which the company reported total revenue of USD 84.2 million, a decrease of 1.7% compared to the same period in the previous year. Net income for the same period was USD 6.6 million, a decrease of 59.8%. This could be indicative of less optimistic financial performance for the company, especially when compared to prior years. However, investors may find potential opportunity in the stock, as the company’s long-term future remains uncertain.
